Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE ACETATE versus UCERIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE ACETATE versus UCERIS.
HYDROCORTISONE ACETATE vs UCERIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone acetate is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression. It exerts anti-inflammatory, immunosuppressive, and vasoconstrictive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Uceris (budesonide) is a corticosteroid with potent glucocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines (e.g., IL-1, IL-2, IL-4, IL-5, TNF-alpha), suppression of arachidonic acid metabolism via phospholipase A2 inhibition, and reduction of inflammatory cell infiltration. It has high topical anti-inflammatory activity and undergoes extensive first-pass hepatic metabolism, minimizing systemic bioavailability.
Hydrocortisone acetate is typically administered as a topical, intra-articular, intradermal, or rectal preparation. For intra-articular use, adult dose: 5-50 mg (depending on joint size) every 1-2 weeks. For rectal use, 25 mg (one suppository) twice daily or 1 application of foam or enema (10% or 1% respectively) once or twice daily. For intradermal injection, 1-2 mL (25 mg/mL) into lesion every 1-2 weeks. Note: Systemic dosing is not applicable as it is not used for systemic effects due to low bioavailability.
For induction of remission in mild to moderate active ulcerative colitis: one 9 mg extended-release tablet orally once daily for up to 8 weeks.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours for endogenous hydrocortisone; with acetate ester, extended to ~2-4 hours due to slower absorption and hydrolysis. Clinical context: Duration of action exceeds half-life due to intracellular receptor binding.
2.8-4.5 hours (terminal). Clinical context: short half-life supports once-daily extended-release formulation for colonic delivery.
Renal: ~80% as metabolites (glucuronide and sulfate conjugates) and <1% unchanged; fecal: <5% via biliary elimination.
Renal: <1%. Fecal: approximately 63% as budesonide and metabolites. Biliary: minor.
Category D/X
Category C
Corticosteroid
Corticosteroid